(Q40337945)

19 September 2017

A novel strategy to compensate the disadvantages of live vaccine using suicide-gene system and provide better antitumor immunity (English)

1 reference

19 September 2017

0 references

1 reference

Yu Kang

1

1 reference

19 September 2017

Cong-Jian Xu

2

1 reference

19 September 2017

Chao-Qun Wu

3

1 reference

19 September 2017

Xi-Shi Liu

4

1 reference

19 September 2017

Cui-Ping Zhong

5

1 reference

19 September 2017

Xin-Hua Zhang

6

1 reference

19 September 2017

Shou-Yi Qiao

7

1 reference

19 September 2017

Jian-Ren Gu

8

1 reference

19 September 2017

language of work or name

English

0 references

publication date

5 December 2005

1 reference

19 September 2017

10

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

19 September 2017

24

1 reference

19 September 2017

12

1 reference

19 September 2017

2141-2150

1 reference

Dendritic cells fused with human cancer cells: morphology, antigen expression, and T cell stimulation.

19 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.023

Dendritic cells: a journey from laboratory to clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.023

Dendritic cell-tumor fusion vaccines for renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.023

Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.023

Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.023

Therapeutic immune response induced by electrofusion of dendritic and tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.023

Curative potential of GM-CSF-secreting tumor cell vaccines on established orthotopic liver tumors: mechanisms for the superior antitumor activity of live tumor cell vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.023

Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.023

Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.023

Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.023

Antitumor effects of combined therapy of recombinant heat shock protein 70 and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.023

Tumor Escape from Immune Response: Mechanisms and Targets of Activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.023

Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.023

Cell fusion: an approach to generating constitutively proliferating human tumor antigen-presenting cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.023

Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.023

Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.023

Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.023

Vaccination of fusion cells of rat dendritic and carcinoma cells prevents tumor growth in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.023

Antitumor immunopreventive and immunotherapeutic effect in mice induced by hybrid vaccine of dendritic cells and hepatocarcinoma in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.023

Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.023

Dendritic cell-tumor cell fusion and staphylococcal enterotoxin B treatment in a pancreatic tumor model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.023

Allogeneic tumor-dendritic cell fusion vaccines for generation of broad prostate cancer T-cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.023

Dendritic cell immunotherapy for patients with metastatic renal cell carcinoma: University of Tokyo experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.023

Allogeneic Dendritic Cells Fused with Tumor Cells: Preclinical Results and Outcome of a Clinical Phase I/II Trial in Patients with Metastatic Renal Cell Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.023

Dendritic cell-tumor cell hybrid vaccination for metastatic cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.023

The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.023

Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.023

Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.023

Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.023

Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.023

In vitro antitumor immune response induced by fusion of dendritic cells and colon cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.023

10.1016/J.VACCINE.2005.11.023

7 January 2021

Identifiers

DOI

1 reference

19 September 2017

1 reference